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Intraperitoneal (i.p.) injection of peptidoglycan-polysaccharide derived from group A streptococci (PG-APS)
causes chronic arthritis with spontaneous remissions and exacerbations. We hypothesized that, following i.p.
injection, PG-APS released from hepatic stores mediated spontaneous recurrences of arthritis. We tested
whether transplanted livers with large amounts of PG-APS were able to reactivate quiescent arthritis.
Saline-loaded (group 1) or PG-APS-loaded (group 2) livers were transplanted into rats which had been injected
intra-articularly 10 days earlier with PG-APS in one joint and saline in the other. A comparison was made with
the arthritis that occurred in rats injected i.p. with PG-APS which did not receive transplants (group 3).
Arthritis was monitored by serial measurement of joint diameters. Transplantation of saline-loaded livers
(group 1) caused no reactivation of arthritis. However, transplantation of PG-APS-loaded livers (group 2)
reactivated arthritis (P < 0.0001). Injection of PG-APS i.p. (group 3) induced the most-severe arthritis.
PG-APS levels in plasma decreased with time, and PG-APS accumulated in the spleen in groups 2 and 3.
Plasma and hepatic levels of PG-APS in rats injected i.p. with PG-APS were greater than levels in rats
transplanted with PG-APS-loaded livers, which in turn were greater than levels in rats with saline-loaded
livers. Plasma tumor necrosis factor did not correlate with recurrence of arthritis. Transplantation with
PG-APS-loaded livers induced reactivation of arthritis in preijured joints. The extent of arthritis was
proportional to hepatic PG-APS content. Reactivation of arthritis may be mediated by slow release of
liver-sequestered PG-APS or cytokines (not tumor necrosis factor) released by the liver.
Systemic injections of poorly biodegradable bacterial cell
wall polymers induce chronic, spontaneously relapsing mul-
tiorgan inflammation in genetically susceptible rats. For
example, a single intraperitoneal (i.p.) injection of pepti-
doglycan-polysaccharide derived from group A streptococci
(PG-APS) induces chronic erosive polyarthritis which under-
goes spontaneous remissions and exacerbations in inbred
Lewis rats (2). This inflammation is biphasic, consisting of
acute nondeforming arthritis, anemia, and mild leukocytosis
and then spontaneous development of erosive arthritis,
granulomatous hepatitis, splenic granulomas and necrosis,
leukocytosis, and anemia with features of the anemia of
chronic disease (18). These chronic features persist for at
least 10 months, during which time two to five spontaneous
reactivations of inflammation occur (18). The phenomenon
of spontaneous reactivation is important because it is a
unique feature of PG-APS-induced inflammation as com-
pared with other agents which cause acute inflammation
alone. The mechanism of spontaneous reactivation of in-
flammation is unknown, and these experiments begin to
explore this area.
Nearly all bacteria contain peptidoglycan-polysaccharide
(PG-PS) in their cell walls, and although these polymers are
very similar, there are subtle differences between the PG-PS
from each different bacterial species. Several factors con-
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tribute to the chronic, spontaneously relapsing inflamma-
tion. (i) Poorly biodegradable PG-PS complexes which per-
sist within inflamed tissues and the reticuloendothelial
system cause chronic inflammation, whereas rapidly degrad-
able PG-PS induces only transient inflammation (3, 23). The
persistence of PG-PS within tissues correlates with the
resistance of these polymers to lytic enzymes. (ii) Inbred rats
demonstrate different genetic susceptibilities to bacterial cell
wall polymers since Lewis rats develop a biphasic response
but Buffalo and Fischer rats develop only transient inflam-
mation (32). (iii) The dose of PG-PS injected affects the onset
and chronicity of inflammation (6, 18). (iv) Since cyclosporin
A and athymic rats (31) and monoclonal antibody against rat
T-cell receptor (33) prevent chronic inflammation induced by
PG-PS, the chronic phase of PG-PS-induced inflammation is
under the control of activated T lymphocytes. (v) The size of
the PG-PS polymers is also important since bacterial cell
wall polymers of smaller molecular size (less than 5 x 106
Da) induce transient acute inflammation, but larger-molecu-
lar-size polymers (5 x 106 to 500 x 106 Da) cause chronic
relapsing inflammation (6).
A unique and unexplained feature of chronic arthritis after
systemic injection of PG-APS is that spontaneous reactiva-
tion occurs during the chronic phase of inflammation. Janusz
et al. and Stimpson and coworkers postulated that PG-PS
sequestered within the reticuloendothelial system (mainly
phagocytic cells in the liver, spleen, bone marrow, and
lymph nodes) is slowly degraded and then released to
reactivate a previously injured joint (9, 27). After i.p. PG-
APS injection, there is rapid uptake by reticuloendothelial
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FIG. 1. Experimental protocol. This figure illustrates the experimental design and describes the groups of rats studied. Group 1 consists
of eight rats which received PG-APS in one ankle joint and saline in the other ankle joint 10 days prior to receiving a liver transplantation.
The donor liver was from a rat which had been injected with saline i.p. 4 days prior to transplantation. Group 2 consists of eight rats which
had received PG-APS in the one ankle joint and saline in the other ankle joint 10 days prior to liver transplantation. The donor was from a
rat which received PG-APS i.p. 4 days prior to transplantation. Group 3 consists of six rats which received PG-APS i.p. and were left intact
until necropsy. Group 4 consists of 12 rats not injected with PG-APS either i.p. or intra-articularly and not transplanted, i.e., normal rats. All
doses of PG-APS are expressed in rhamnose weight, which is approximately 30% of the PG-APS dry weight.
cells. The liver sequesters 10% of PG-APS 4 days after i.p.
injection (4, 8), mostly localized to Kupffer cells (3), and this
is the greatest amount of PG-APS found in a single organ.
Forty-five days after i.p. injection, liver tissue concentra-
tions decreased to approximately 1% of the initial injected
dose, presumably by release into draining blood or lymphat-
ics or by degradation by endogenous muralytic enzymes
such as lysozyme (8, 27). It is postulated that PG-APS
released from sequestered sites such as Kupffer cells redis-
tributes to other tissues including the joint and may account
for periodic reactivation of arthritis. Stimpson et al. demon-
strated that PG-APS polymers in the blood and joints were
smaller than the polymers found in the liver (27) and that
liver extracts were able to degrade PG-APS (28). These
findings indicate that the reticuloendothelial system releases
partially degraded PG-APS polymers (28). Furthermore,
local or systemic injection of PG-APS polymers can reacti-
vate arthritis in a previously injured joint (5).
Thus, considerable indirect evidence suggests that slow
release of partially degraded PG-PS by the liver and other
reticuloendothelial organs may reactivate experimental ar-
thritis. In the present study, we directly test this hypothesis
by determining whether transplanted rat livers, loaded with
sequestered PG-APS, are able to reactivate arthritis.
In these studies, we used a model in which reactivation of
arthritis is sensitive to circulating PG-PS polymers (5). A
single intra-articular injection of PG-APS into the tibio-talar
(ankle) joint of a Lewis rat causes a self-limited, monoartic-
ular arthritis that becomes clinically quiescent 10 to 21 days
after intra-articular injection. Reactivation of arthritis can be
achieved by systemic injections of PG-PS (5), purified pep-
tidoglycan (5), endotoxin (26), or superantigen (21), intra-
articular injection of platelet-derived growth factor, tumor
necrosis factor alpha (TNF-a) (24, 29), or interleukin-1 (20,
25), and creation of small-bowel bacterial overgrowth (11).
The intravenous dose of PG-APS necessary to reactivate
arthritis in this model is very small, only 50 to 100 ,ug of
rhamnose, which is 1 to 3% of the i.p. injected dose required
to initiate chronic relapsing arthritis (20). In the present
study, we found that transplantation of livers that had
accumulated PG-APS caused reactivation of arthritis, sug-
gesting that hepatic release of PG-APS polymers or cyto-
kines can reactivate joint inflammation in this model.
MATERIALS AND METHODS
Experimental design. On day 0, 16 male, specific-patho-
gen-free Lewis rats (Charles River, Raleigh, N.C.) weighing
250 g were injected intra-articularly with 10 ,ul of PG-APS in
a dose of 2.5 p,g of rhamnose into one ankle joint, and 10 ,ul
of pyrogen-free saline was injected into the contralateral
ankle joint, as described previously (5). The PG-APS-in-
jected joint was called the preinjured joint; the saline-
injected joint was called the control joint. On day 10, when
arthritis in the PG-APS-injected ankle was resolving, liver
transplantation was performed (Fig. 1). Eight intra-articu-
larly injected rats received a donor liver from rats which had
received an i.p. injection of an arthropathogenic dose of
PG-APS (PG-APS-loaded liver, group 2), and the other eight
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which had been injected i.p. with pyrogen-free saline (saline-
loaded liver, group 1). Donor male Lewis rats were injected
i.p. with PG-APS (3,750 ,ug of rhamnose; 15 tig/g of body
weight) or i.p. with saline 4 days prior to removal of the liver
for transplantation. PG-APS-injected rats developed acute
arthritis prior to harvest of the liver for transplantation,
indicating a systemic effect of PG-APS. Additionally, six
male Lewis rats were injected i.p. with PG-APS (15 p,g of
rhamnose per g of body weight) but were left intact and not
used as donors (group 3). These rats were killed 60 days after
i.p. injection of PG-APS to measure the PG-APS contents in
livers and spleens for comparison with those of rats which
received transplanted livers. Tissues from 12 rats which had
not been injected with PG-APS and which had received no
liver transplantation were assayed for background levels of
PG-APS (group 4).
Joint diameters were measured daily in duplicate by a
blinded observer with a micrometer (25, 30) from day 0 to 21
and then weekly thereafter. Rats were weighed weekly.
Plasma was drawn from the tail vein on day 0, every other
day between days 10 to 21, and then weekly thereafter for
determination of PG-APS, aspartate aminotransferase, and
TNF-a levels.
When the experiment was completed 56 days after liver
transplantation, the rats were killed by CO2 inhalation, and
the livers, spleens, and joints were harvested for histology
and measurement of PG-APS levels by enzyme-linked im-
munosorbent assay (ELISA). As summarized in Fig. 1, the
four groups of rats studied included (i) 8 rats with preinjured
ankle joints which received saline-loaded livers by transplan-
tation (group 1), (ii) 8 rats with preinjured ankle joints which
received PG-APS-loaded livers by transplantation (group 2),
(iii) 6 rats with no prior joint injury which received i.p.
PG-APS and were left intact (group 3), and (iv) 12 rats which
received no PG-APS and no liver transplantation (group 4).
Transplantation of livers. Rat livers were transplanted
under ether anesthesia as described by Steffen et al. (22) and
Kamada and Calne (10). To avoid rejection and graft-versus-
host disease, syngeneic male Lewis rats (250 g) were used as
recipients and donors. Donor livers were flushed via the
portal vein with chilled University of Wisconsin solution
(Madison, Wis.), cuffs were attached, and the explants were
stored in University of Wisconsin solution at 4°C. Before
implantation, the donor grafts were infused with 30 ml of
Carolina rinse solution at 28 to 30°C (1). Recipient surgery
including hepatectomy and transplantation required approx-
imately 60 min. During this time, the portal vein was
clamped for 15 min and the inferior vena cava was clamped
for not more than 20 min. Rats were given food and water ad
libitum postoperatively.
Measurement of TNF-. Plasma samples were collected in
aprotinin (0.67 trypsin inhibitor unit (TIU)/ml) and EDTA
(1.5 mg/ml) as described previously (13), centrifuged, and
stored at -70°C until assayed. A murine TNF-ce ELISA kit
(Genzyme, Boston, Mass.) was used (13). Ninety-six-well
microtiter plates were coated with hamster anti-TNF-a
antiserum in 100-pl volumes and incubated at 4°C overnight.
After the plates were washed with phosphate-buffered sa-
line-0.1% Tween 80 buffer, blocker was added for 2 h at
room temperature. After the plates were washed, samples
were diluted at least 1 to 4, applied in 100-pl volumes, and
allowed to incubate for 18 h at 4°C. The plates were washed,
donkey anti-TNF-a antiserum was added for 3 h at room
temperature, and the plates were washed again. The goat
anti-donkey peroxidase conjugate was then applied for an-
other 3 h. The plates were washed, the substrate solution
was applied, and color changes were monitored with an
ELISA reader (Dynatech, Chantilly, Va.) at an optical
density of 450 nm after 5 min. The assay measures murine
TNF-a in the range of 50 to 1,000 pg/ml, which were
concentrations used to construct a standard curve.
Preparation of PG-APS. The culture and harvesting of
group A streptococci, isolation of the cell walls, and sepa-
ration of the PG-APS fragments have been described in
detail (27, 30). The amount of PG-APS in each preparation
was determined by measurement of rhamnose (30), which
constitutes approximately one-third of the dry weight of
PG-APS. All values of PG-APS stated in these studies are
expressed in rhamnose weight.
Measurement of PG-APS. Livers and spleens were homog-
enized in a tissue grinder in Tris buffer (pH 7.4) with 0.1%
Tween 80 and 1% human serum albumin in a ratio of 4 ml
of buffer to 1 g of tissue. Joints were frozen in liquid
nitrogen, pulverized in a steel chamber with a hammer,
diluted in Tris-0.1% Tween 80-1.0% human serum albumin
buffer, and then sonicated (Ultrasonics, Farmingdale, N.Y.)
for 60 s (4).
PG-APS was measured by ELISA as described previously
(12). Briefly, 96-well microtiter plates were coated for 18 h at
4°C with affinity-purified rabbit anti-N-acetylglucosamine
antibody. After the plates were washed with PBS-0.1%
Tween 80 buffer, 0.1% bovine serum albumin was applied to
prevent nonspecific binding. Diluted samples were then
added and incubated for 18 h at 4°C. After the plates were
washed, biotinylated affinity-purified rabbit anti-N-acetyl-
glucosamine antibody was added for 3 h at room tempera-
ture. Plates were again washed, and avidin conjugated with
alkaline phosphatase was added for another 3 h. The color
reaction was developed by using p-nitrophenyl phosphate
substrate (substrate tablets; Sigma Chemical Co., St. Louis,
Mo.), and the A405 was measured 30 min later with a
Dynatech ELISA reader. The amount of PG-APS was cal-
culated from a standard curve for purified PG-APS based on
rhamnose content.
Measurement of anti-PG-PS antibodies. Anti-PG-APS an-
tibodies were measured in joint tissues which were frozen
and pulverized as described above. Anti-PG-APS immuno-
globulin G (IgG) and IgM were measured by an ELISA as
described previously (12). Briefly, 96-well microtiter plates
were coated with 100 ,ul of a 2-ug/nml concentration of
PG-APS prepared as described above. After 18 h of incuba-
tion at 4°C, the plates were washed and blocked with 0.1%
bovine serum albumin for 2 h at 25°C. Samples ofjoint tissue
were diluted at least fourfold and applied to the plates for 18
h at 4°C. Alkaline phosphatase-conjugated goat anti-rat IgG
or IgM (Sigma) was added for 8 h at 4°C, and then color was
developed with the Sigma substrate tablets as described
above. The optical density was measured at 405 nm after 90
min for this assay.
Histological techniques. When rats were killed, specimens
of liver were fixed in 10% buffered formalin and then
processed for histological examination and stained with
hematoxylin and eosin. For the determination of number and
location of granulomas and the number of nonparenchymal
cells, slides were coded and read blindly by a single observer
(S.N.L.).
Statistics. Weights, plasma aspartate aminotransferase,
hematocrits, and PG-APS and TNF-a levels were compared
by using the two-tailed Student's t test. Joint diameters were
compared by using repeated-measure analysis of variance.
Differences were considered statistically significant when P
was <0.05.
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TABLE 1. Clinical and laboratory data for rats after
liver transplantation
Aspartate
Expt No. of aminotransferase Wt gain Hematocrit
group n deaths (U/liter)a (g)a
Day 14 Day 56
lb 8 0 87 ± 13 94 ± 15 77 ± 13 43 ± 2.8
2C 7 0 79 ± 19 74 ± 19 78 ± 31 43 ± 1.6
a All values are means + standard deviations at the time of necropsy (56
days after transplantation) unless otherwise noted.
Rats killed 56 days after being transplanted with livers from rats injected
i.p. with saline.
c Rats killed 56 days after being transplanted with livers from rats injected
i.p. with PG-APS (15 jLg of rhamnose per body weight), 4 days before
transplantation.
RESULTS
Surgical outcome. No rats in either group which had liver
transplantation died. The arterial anastomosis was unsuc-
cessful in one rat, which survived but developed an in-
creased bilirubin level of 11.4 mg/dl. Despite surviving until
the end of the experiment, the rat showed poor weight gain,
a low hematocrit, and massive bile duct proliferation on
histologic examination of the liver. This rat had received a
PG-APS-loaded liver transplantation and was excluded from
the study. The other rats which received grafts all grew
similarly, with initial weight loss for 10 to 14 days and then
gradual weight gain until they were killed. Weight gains,
hematocrits, and plasma aspartate aminotransferase values




















saline-loaded livers and those with PG-APS-loaded liver
transplantations (Table 1).
Joint swelling. The mean changes in the preinjured joint
diameters of groups 1, 2, and 3 are shown in Fig. 2 and 3A.
In rats injected i.p. with PG-APS (group 3), both joints
developed arthritis, and the right ankle joint was not signif-
icantly more swollen than the left ankle joint. The left ankle
was arbitrarily chosen to be compared with the preinjured
joints of groups 1 and 2. Preinjured ankle joints, which were
injected with PG-APS, showed reactivation of arthritis fol-
lowing transplantation with PG-APS-loaded livers (Fig. 2
and 3A). Both the absolute joint diameters (data not shown)
and the change in joint diameters were significantly greater
in rats that received PG-APS-loaded livers by transplanta-
tion than in those that received saline-loaded livers. An
example of the gross swelling of a joint during an episode of
reactivation of arthritis is shown in Fig. 4. The peak joint
diameters occurred 42 days after transplantation of PG-APS-
loaded livers and after i.p. injection of PG-APS. Rats which
received PG-APS i.p. (group 3) showed the greatest increase
in joint diameters for both ankles, neither of which had been
preinjured intra-articularly with PG-APS.
In Fig. 3, the changes in joint diameter of each rat are
illustrated. An increase in joint diameter is considered sig-
nificant when it is greater than 0.30 mm. Five of seven rats
which received PG-APS-loaded livers (group 2) had an
increase in the preinjured joint diameter of more than 0.30
mm compared with two of eight rats with increased joint
diameters in the saline-loaded liver controls (group 1). By
using repeated-measure analysis of variance, we found
highly significant differences among groups 1, 2, and 3 (P <
7 14 21 28 35 42 49 56
Days
FIG. 2. Change in joint diamneters after i.p. injection of PG-APS (group 3; 0), transplantation with PG-APS-loaded livers (group 2; *), and
transplantation with saline-loaded livers (group 1; *). Groups 1 and 2 had been preinjured with an intra-articular injection of PG-APS 10 days
prior to surgery. Values represent means + standard errors. The horizontal axis refers to time in days after i.p. injection of PG-APS or liver
transplantation surgery. On days 35, 42, and 49, the changes in joint diameter were significantly greater in groups 2 and 3 than in group 1 (rats
which received saline-loaded livers), as determined by the Student's t test (P < 0.05).
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FIG. 3. Individual change in joint diameters for both ankle joints of each rat following i.p. injection of PG-APS and liver transplantation.
The horizontal axis represents time in days after i.p. injection of PG-APS or liver transplantation. (A) Changes in joint diameter in preinjured
(PG-APS-injected) ankle joints of groups 1 and 2 and the arbitrarily chosen left joint of group 3. (Top) Changes in joint diameter of rats which
received intra-articular PG-APS and then a saline-loaded liver transplantation 10 days later (group 1). These joints showed no significant
increase in diameter after transplantation. (Middle) Results of rats which received intra-articular PG-APS and then a PG-APS-loaded liver
transplantation 10 days later (group 2). (Bottom) Change in joint diameter after i.p. injection of PG-APS (group 3). By using repeated-measure
analysis of variance, the three groups demonstrated significant differences (P < 0.0001). (B) Changes in Control (saline-injected) ankle joints
of rats in groups 1 (top) and 2 (middle) and the right ankle of group 3 (bottom). Only joints from rats injected i.p. with PG-APS (group 3)
demonstrated statistically significant increases in diameter. However, saline-injected joints in three of seven rats which received
PG-APS-loaded livers (group 2) showed an increased joint diameter greater than or equal to 0.3 mm, which indicates arthritis.
0.0001). Control ankle joints, injected with pyrogen-free
saline, showed no significant change in diameter regardless
of the source of the transplanted liver (Fig. 3B).
Plasma and tissue PG-APS levels. When rats were killed 56
days after transplantation, hepatic PG-APS levels were
markedly greater in those animals which received PG-APS-
loaded livers than those which received saline-loaded livers
(P < 0.001; Table 2). Transplanted PG-APS-loaded livers
had 17-fold less PG-APS than livers of rats which received
PG-APS i.p. but were left intact (group 3). Saline-loaded
livers contained amounts of PG-APS similar to those in
livers from rats never injected intra-articularly or i.p. with
PG-APS (normal rats). To create group 2, the rats were
initially injected i.p. with PG-APS (3,750 jig of rhamnose),
the livers were removed after 4 days and transplanted to a
new host, and the rats were then killed 56 days later. At this
time, the livers contained 1.74 ,ug of rhamnose, which is
0.05% of the initial i.p. injected dose of PG-APS. Rats in
group 3 also were initially injected with PG-APS (3,750 ,ug of
rhamnose) i.p. but were left intact. Thirty micrograms of
rhamnose was recovered from the livers of rats from group 3
(i.e., 0.80% of the original i.p. dose of PG-APS), which was
significantly greater than the amount recovered from trans-
planted PG-APS-loaded livers (Table 2; P < 0.001).
PG-APS concentrations in spleens of rats receiving PG-
APS i.p. but left intact (group 3) were 15-fold higher than the
concentrations in spleens of rats which had received PG-
APS-loaded livers by transplantation (group 2). However,
splenic PG-APS levels in group 2 were 33-fold greater than
levels in spleens of rats transplanted with saline-loaded










4650 LICHTMAN ET AL.
FIG. 4. Photograph of rat ankle joints. The preinjured right ankle
joint had been injected at the beginning of the experiment with
PG-APS (2.5 Fg of rhamnose) in a 10-plA volume; the left ankle joint
had been injected with 10 pl of saline. Forty-two days after
transplantation with a liver which had been PG-APS loaded, the
right ankle joint showed increased diameter, swelling, redness, and
decreased range of motion compared with the left ankle joint.
By 56 days, differences in the amounts of PG-APS in joint
tissue between the groups were not statistically significant,
as measured by ELISA (Table 2). Joints injected with
PG-APS did not have significantly higher PG-APS concen-
trations in tissue than the saline-injected contralateral joints
56 days after transplantation. Similarly, joints injected intra-
articularly with PG-APS showed no significant differences in
PG-APS content whether the rat received a saline-loaded or
a PG-APS-loaded liver. Since anti-PG-APS antibody in joint
tissue could potentially block PG-APS measurement by
ELISA, anti-PG-APS IgG and IgM were measured in joint
tissues, but no differences were found in antibody levels
among the different groups of rats or between PG-APS-
injected and saline-injected joints (data not shown). The
addition of a known amount of PG-APS to joint tissue
samples was 80 to 110% recovered, as measured by ELISA,
indicating that no inhibitor to the detection of PG-APS by
ELISA was present in joint tissue. Therefore, by using an
ELISA at the end of the experiment, we could demonstrate
no significant differences in PG-APS content between the
ankle joints.
In group 2, the highest plasma level of PG-APS occurred
at the first measurement, 2 days posttransplantation, and
then progressively declined (Table 2). Considering a blood
volume of 8% of total body weight, the amount of circulating
PG-APS in the blood of a 250-g rat at 2 days posttransplan-
tation (the time point with the highest measurement) would
be 500 ng. Plasma PG-APS levels were not increased by
intra-articular injection of PG-APS. At each time point until
day 42, plasma PG-APS levels were consistently higher in
rats which received PG-APS i.p. (group 3) than in those
which were transplanted with a PG-APS-loaded liver (group
2), which, in turn, were higher than plasma PG-APS levels of
rats with saline-loaded livers.
Plasma TNF-a levels. Plasma TNF-a levels in rats with
saline-loaded livers did not change with time, were only
slightly higher than levels in normal rats, and were at the
lower end of detection by an ELISA. However, plasma from
rats with PG-APS-loaded livers had elevated TNF-a levels
measured between days 35 and 49. The peak plasma TNF-a
level 42 days after transplantation with a PG-APS-loaded
liver (121 + 42 pg/ml [mean + standard deviation]) was
greater than the plasma TNF-a level in rats transplanted
with a saline-loaded liver (48 + 11 pg/ml; P < 0.05).
Compared with controls, no significant increase in plasma
TNF-a levels were detected in rats following i.p. injection of
PG-APS (group 3) despite greater joint swelling at all time
points.
Liver inflammation. When rats were killed 56 days after
transplantation, there were no visible surface granulomas in
the transplanted livers that had been loaded with PG-APS
(group 2). The lack of surface granulomas is in contrast to
TABLE 2. Tissue and plasma PG-APS levels after liver transplantation
PG-APS levels in:
Expt n Plasma (ng/ml) on day:group Liver Spleen Joints
(ng/liver)a (ng/spleen)a (ng/g)a 2 14 28 35 42 49 56
1 8 35 ± 8 1.8 ± 1.8 11 ± 6b 0.3 ± 0.4 2.4 ± 1.5 2.0 ± 1.3 1.5 ± 0.9 1.4 ± 1.0 1.7 ± 1.1 0.9 ± 0.7
8 ± 6c
2 7 1,740 ± 340d 59 ± 8d 13 + 7b 25 ± 8d 1.5 ± 3d 5.0 ± 1.9d 3.3 ± 1.6e 1.5 ± 0.3 1.2 ± 0.5 1.3 ± 0.5
9 ± 7c
3f 6 30,000 ± 4,500dg' 860 ± 112"'g 24 ± 18 177 ± 47g 93 ± 22g 21 ± 5g 9.1 ± 4.0' 3.3 + 1.29 1.8 ± 0.7 1.7 ± 0.7
4 12 28 ± 12 2.1 ± 1.0 9 + 5
a Mean + standard deviation of PG-APS in tissue 56 days after liver transplantation.
b Value for joints which had been injected intra-articularly with PG-APS.
c Value for joints which had been injected with pyrogen-free saline.
d Compared with rats with saline-loaded livers, P < 0.001.
I Compared with rats with saline-loaded livers, P < 0.05.
f Rats injected i.p. with PG-APS (15 ,ug of rhamnose per g of body weight) but not used as donors.
g Compared with rats with PG-APS-loaded livers, P < 0.005.
h Rats which have never been injected with PG-APS.
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TABLE 3. Histology of livers from normal rats compared with those of livers 56 days after transplantation
and after injection of PG-APS
Expt group No. of animals No. of microscopic No. of N in:granulomasa) Portal tract-'. Parenchyma,'d Central vein area,,'
1 8 0 30.6 ±3.9 4.7 ±0.7 13.8 + 2.7
2 7 3.5 + 4.3f 40.2 ± 14.1 9.2 1.4g 21.3 3.9g
3 6 16.6 ± 4.6gi 57.2 ± 3.9g"' 11.6 ± 0.7k-A 31.2 ± 8.4&^
4 12 0 28.8 ± 4.2 6.3 + 0.5 12.6 + 1.2
a All values are means + standard deviations.
b Number of granulomas in a 2-cm2 section of liver.
c Number of nonparenchymal cells (NPCs) in a portal tract of a 30-p.m-diameter portal vein.
d Number of nonparenchymal cells (NPCs) in an area 30 by 10 p.m.
Number of nonparenchymal cells (NPCs) surrounding a central vein with a 30-p.m diameter.
f Compared with rats with saline-loaded livers, P < 0.05.
g Compared with rats with saline-loaded livers, P < 0.001.
h Compared with rats with PG-APS-loaded livers, P < 0.02.
Compared with rats with PG-APS-loaded livers, P < 0.001.
the numerous grossly evident granulomas that were found on
examining the livers of the rats injected i.p. with PG-APS
(group 3) and not used as donors. This observation was
confirmed histologically since livers from rats injected i.p.
with PG-APS (group 3) had 9 to 22 granulomas per 2-cm2
section of liver tissue whereas livers which were PG-APS-
loaded and then transplanted (group 2) had 0 to 9 granulomas
per 2-cm2 section of liver tissue (Table 3).
Architecture was maintained and necrosis and fibrosis
were minimal in transplanted saline-injected livers and PG-
APS-loaded livers, although some microscopic granulomas
were present in the latter group. Nonparenchymal cells
(chronic inflammatory cells and Kupffer cells) were in-
creased in PG-APS-loaded livers compared with saline-
loaded livers in the portal tracts, around central veins, and in
the parenchyma (Table 3). Nonparenchymal cells included
mostly liver macrophages (resident Kupffer cells and newly
recruited macrophages), although some endothelial cells,
fat-storing cells, and lymphocytes were likely counted as
well. Nonparenchymal cells were most numerous in livers
from rats with the i.p. PG-APS injection (group 3), followed
by transplanted PG-APS-loaded livers (group 2), and then
transplanted saline-loaded livers (group 1), which were sim-
ilar to normal rats (Table 3).
DISCUSSION
Spontaneous recurrence of polyarthritis in rats after i.p.
injection of PG-APS and reactivation of monoarticular ar-
thritis in PG-APS-injected joints bear considerable resem-
blance to flares of arthritis in patients with rheumatoid
arthritis and arthritis associated with inflammatory bowel
disease. To better understand the mechanism of spontane-
ous recurrences of arthritis following i.p. injection of PG-
APS, we determined whether PG-APS-loaded livers could
reactivate arthritis in previously injured joints. The main
findings of these studies were that (i) transplantation of
PG-APS-loaded livers did cause reactivation of arthritis and
(ii) PG-APS sequestered within the transplanted livers was
disseminated to the blood and spleen. Transplantation of
PG-APS-loaded livers caused reactivation of arthritis in
joints which had been injured previously by PG-APS. Swell-
ing in contralateral saline-injected joints was not consistently
greater in rats which received a PG-APS-loaded liver. Pre-
injured joints are more sensitive to recurrent inflammation
than noninjured joints (5, 25, 29).
The data presented in this study provide direct evidence
that bacterial cell wall polymers can be released from depot
stores in the liver. In previous studies, 45 days after i.p.
PG-APS injection, 1% of the initial dose was recovered in
the liver (8, 27). Those results are in close agreement with
our present results since livers from rats which received
PG-APS i.p. and left intact (group 3) retained 0.8% of the
injected material. However, only 0.05% of the original i.p.
dose was retained in the liver 56 days after transplantation
(group 2). Therefore, in rats injected i.p. and not further
manipulated (group 3), PG-APS sequestered in nonhepatic
sites (spleen, peritoneal cavity, lymph nodes, or bone mar-
row) must play an important role in maintaining liver PG-
APS levels. This suggests that PG-APS recirculates between
extrahepatic sites and the liver. Gradual release of PG-APS
from the liver is demonstrated by elevated levels in the
plasma and accumulation within the spleen. We hypothesize
that there is a constant flux (release and uptake) of PG-APS
from sequestered pools into and out of the liver. The
mechanism for such release of PG-APS from the liver is
unknown but may include transport into bile (14), release of
partially degraded PG-APS from Kupffer cells into blood,
and release from dying cells. It should be emphasized in the
present study that, prior to transplantation, livers were
perfused twice so that no freely circulating PG-APS was
initially available to the donor.
Our results give insight into the mechanism for spontane-
ous reactivation of PG-APS-induced arthritis. We had hy-
pothesized that PG-APS released from the transplanted liver
would travel to the injured joint and induce reactivation of
arthritis. Our data do not support this hypothesis entirely
since (i) PG-APS levels in the joint were not increased in rats
with reactivation of arthritis and (ii) elevated plasma PG-
APS levels did not correlate with reactivation of arthritis.
There are several reasons why PG-APS levels in joints
may not be elevated in rats with reactivation of arthritis.
Joints were examined only at the end of the experiment,
several weeks after peak reactivation of arthritis occurred,
so that an earlier accumulation of PG-APS may have been
missed. Janusz et al. found a steady decline in PG-APS
within joints of rats injected i.p. with PG-APS from 700 to 80
ng/g of tissue 36 days later (8). Our value 56 days after
transplantation was approximately 24 ng/g of tissue in group
3, which was not statistically greater than levels in group 2.
PG-APS levels in joints may be at the lower range of
sensitivity with our ELISA system. The lack of elevated
levels of PG-APS within the joints could not be attributed to
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anti-PG-PS antibodies or an inhibitor in the ELISA system.
Finally, reactivation of arthritis may not be caused by
accumulation of PG-APS within the joint.
Circulating PG-APS levels did not temporally correlate
precisely with reactivation of arthritis, but rats with a greater
total body load of PG-APS had more severe arthritis. Rats in
group 3 had a larger PG-APS load than rats in group 2. Sartor
et al. (18) found that if the i.p. dose of PG-APS was
decreased from 15 to 5 ,ug of rhamnose/g of body weight,
only 40% of rats developed the chronic phase of arthritis and
the onset of chronic relapsing arthritis was delayed from 28
to 50 days.
In previous experiments, intravenous injection with small
doses of PG-APS induced a flare of arthritis within 6 h which
peaked at 3 days (5). However, small amounts of PG-APS
consisted of an intravenous bolus of 100 p,g of rhamnose
(20), which would lead to a calculated immediate plasma
level of 5 p,g of rhamnose per ml, assuming the blood volume
to be 20 ml. The highest plasma levels measured in these
experiments was only in the nanogram per milliliter range.
Our experiments cannot exclude the possibility that reacti-
vation of arthritis was induced by slow, continuous release
of PG-APS from a transplanted liver. Continuous release of
PG-APS with sustained blood levels may have entirely
different kinetics than that of a single bolus injection. In
addition, reactivation of arthritis may require a minimal
accumulative dose of PG-APS which is rapidly achieved
after intravenous bolus treatment but requires a longer time
when release is gradual. The stress of transplantation sur-
gery may have caused release of cortisol and other protec-
tive mediators which may have delayed immediate reactiva-
tion of arthritis during the first weeks after surgery.
Was reactivation of arthritis secondary to release of cyto-
kines from an inflamed liver? This hypothesis is reasonable
since livers from rats in group 3 had more inflammatory cells
than those in group 2, and this corresponded to more-severe
arthritis in group 3 than group 2. The plasma TNF-a level in
rats with PG-APS-loaded livers was slightly elevated com-
pared with that in saline-loaded livers 42 days after trans-
plantation, but the interpretation of this finding is uncertain.
At no time point were plasma TNF-cx levels increased after
i.p. injection of PG-APS despite greater changes in joint
diameter and more abnormal liver histology. Liver macro-
phages are capable of producing large amounts of TNF-a
when stimulated with PG-APS (15, 17), and Kupffer cells
sequester the majority of PG-APS in the liver (3, 16).
However, peak levels of TNF-a after macrophage stimula-
tion are transient and disappear within several hours. In
general, one must be cautious when trying to correlate
plasma TNF-a levels to events occurring in the joint. TNF-a
within joints is probably more relevant since intra-articular
injection of TNF-a can reactivate arthritis (24), but serial
joint measurements were not possible in this experimental
protocol. Other cytokines such as interleukin-1 (20, 25) and
platelet-derived growth factor (29), which can also reactivate
arthritis in PG-APS-injured joints, could also be important
but were not examined.
This animal model may be relevant to human arthritis
since absorption of bacterial cell wall polymers such as
endotoxins and PG-PS can occur from the intestinal lumen,
with enhanced uptake across injured intestinal mucosa (19).
These polymers then enter the portal vein and are phagocy-
tosed by macrophages (Kupffer cells) of the liver. The fate of
endotoxin has been studied extensively in animals and
shows mostly detoxification and elimination (7), but the fate
of PG-PS is less well known. Luminal PG-APS is absorbed in
increased amounts in rats with small-bowel bacterial over-
growth (10), where it is deposited in the liver. After experi-
mental colonic injury, luminal PG-APS was detected in the
liver, spleen, and cardiac blood (19).
These studies begin to investigate the mechanism of
reactivation of arthritis induced by bacterial cell wall poly-
mers. Further studies need to examine (i) the role of other
cytokines (e.g., interleukin-1 and platelet-derived growth
factor) which may originate within the joint or from extra-
articular sites and (ii) the role of sensitized T cells in
reactivation of arthritis. Our results demonstrate that nonar-
ticular stores of PG-APS, particularly hepatic stores, can be
disseminated to the systemic circulation and the reticuloen-
dothelial system. As well, the pool of PG-APS sequestered
in nonarticular tissues (liver, spleen, lymph nodes, perito-
neal cavity, and bone marrow) can cause reactivation of
arthritis. Poorly biodegradable PG-PS originating from the
intestinal lumen is an excellent candidate for a bacterial cell
wall polymer which could accumulate within a hepatic depot
and induce reactivation of arthritis in humans.
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